Pediatric Oncology Advances Could Prompt More FDA-Required Studies
Executive Summary
Findings being presented at ASCO next month could signify major increase in targets relevant to pediatric oncology, meaning sponsors should prepare for more US FDA-required studies under the RACE for Children legislation.
You may also be interested in...
Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi
Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it the third tumor-agnostic and second NTRK-fusion approval in the US.
Roche Outlines Use Of Real-World Evidence In Entrectinib NDA
Roche used its Flatiron Health oncology EHR database to generate an external control arm for pivotal single-arm data supporting the personalized medicine candidate, which has an 18 August user fee goal.
Oncology Sponsors Getting A Jump On Pediatric Study Requirements, US FDA Says
Beginning in August 2020, applications for some novel cancer drugs and biologics will have to include reports on molecularly targeted pediatric investigations; agency is already working with sponsors on pediatric study development plans and expects to issue two draft guidances soon.